Diabetes is also
known as a critical and noisy disease. Hyperglycemia,
that is, increased blood glucose level is a common effect of uncontrolled
diabetes, and over a period of time can cause serious effects on health
such as blood vessel damage and nervous system damage. However, many
attempts have been made to find suitable and beneficial solutions
to overcome diabetes. Considering this fact, we synthesized a novel
series of indoline-2,3-dione-based benzene sulfonamide derivatives
and evaluated them against α-glucosidase and α-amylase
enzymes. Out of the synthesized sixteen compounds (1–16), only three compounds showed better results; the IC50 value was in the range of 12.70 ± 0.20 to 0.90 ± 0.10
μM for α-glucosidase against acarbose 11.50 ± 0.30
μM and 14.90 ± 0.20 to 1.10 ± 0.10 μM for α-amylase
against acarbose 12.20 ± 0.30 μM. Among the series, only
three compounds showed better inhibitory potential such as analogues 11 (0.90 ± 0.10 μM for α-glucosidase and
1.10 ± 0.10 μM for α-amylase), 1 (1.10
± 0.10 μM for α-glucosidase and 1.30 ± 0.10
μM for α-amylase), and 6 (1.20 ± 0.10
μM for α-glucosidase and 1.60 ± 0.10 μM for
α-amylase). Molecular modeling was performed to determine the
binding affinity of active interacting residues against these enzymes,
and it was found that benzenesulfonohydrazide derivatives can be indexed
as suitable inhibitors for diabetes mellitus.